Epratuzumab
| Disease area studied | Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Systemic Lupus Erythematosus | Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) | Phase 2 |
SL0002
Terminated |
NCT00113971 | "Hobbs et al. Ann Rheum Dis. 2011;70(Suppl 3):319, abs THU0425. European League Against Rheumatism (EULAR) 2011. May 25-28, 2011;London, UK." | ||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus | Phase 3 |
SL0003
Terminated |
NCT00111306 2005-000705-59 |
Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. | ||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) | Phase 3 |
SL0004
Terminated |
NCT00383214 2005-000706-31 |
Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. | ||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus | Phase 3 |
SL0005
Terminated |
NCT00382837 | |||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus | Phase 2 |
SL0006
Completed |
NCT00383513 | Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. | ||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease | Phase 2 |
SL0007
Completed |
NCT00624351 2007-002566-35 |
Wallace et al. Ann Rheum Dis;2014;73(1);183-190. | ||
| Systemic Lupus Erythematosus | Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease | Phase 2 |
SL0008
Completed |
NCT00660881 2007-002589-37 |
Wallace, D. J. et al. Arthritis Care Res (Hoboken);2016;68;4;534-543 | ||
| Systemic Lupus Erythematosus | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1) | Phase 3 |
SL0009
Completed |
NCT01262365 2010-018563-41 |
LINK LINK |
Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 | |
| Systemic Lupus Erythematosus | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2) | Phase 3 |
SL0010
Completed |
NCT01261793 2010-018565-26 |
LINK LINK |
Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 | |
| Systemic Lupus Erythematosus | Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4) | Phase 3 |
SL0012
Completed |
NCT01408576 2010-020859-30 |
LINK LINK |
||
| Systemic Lupus Erythematosus | Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects | Phase 2 |
SL0027
Completed |
NCT01534403 |